Neoadjuvant immunotherapy is characterized by an increase in tumour-specific CD8+cells, suggesting a role in T cell priming or in T cell migration into the tumour, although further research is needed to decipher immune mechanisms implicated. This evidence concerns the gene CD8A and neoplasm.